KNOMATIC

chemical and biochemical preparations and substances for medical purposes for treatment and/or diagnosis of cancer, autoimmune disease, and other diseases that involve the functionality of highly dynamic proteins; immunotherapy products, namely, pharmaceutical preparations for the treatment of cancer, autoimmune diseases, and immunological disorders

drug discovery services; pharmaceutical research services; pharmaceutical products development; pharmaceutical research and development; pharmaceutical drug development services; consulting services in the field of pharmaceutical research and development; technical consulting in the field of pharmaceutical studies; technical research in the field of pharmaceutical studies; research and development services of new pharmaceutical products; research and development in the pharmaceutical and biotechnology fields; providing medical research information in the field of pharmaceuticals; providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research in the field of bioinformatics; biological and bio-technology analysis services; DNA sequencing technology research; research in the field of DNA mutation; DNA analysis services for scientific research purposes; providing genetic science information; scientific research consulting in the field of pharmaceuticals and drug discovery; medical and scientific research in the field of proteomics; scientific research for medical purposes in the field of proteomics; structural and functional analysis of genomes; software as a service (SAAS) services in the nature of a drug discovery platform that utilizes structural analysis, hit finding techniques and computational analysis and targets diseases related to highly dynamic proteins; software as a service (SAAS) services in the nature of drug design and structure activity relationships; software as a service (SAAS) services featuring software for drug discovery, pharmaceutical research and development, and medical research and development; · software as a service (SAAS) services in the nature of DNA encoded library (DEL) screening; software as a service (SAAS) services in the nature of genetic sequencing software; software as a service (SAAS) services featuring software using artificial intelligence (AI) for drug discovery, pharmaceutical research and development, and medical research and development; software as a service (SAAS) services featuring software using machine learning for drug discovery, pharmaceutical research and development, and medical research and development; drug discovery software platform as a service particularly targeting diseases related to highly dynamic proteins by utilizing structural analysis, hit finding techniques and computational analysis; software as a service (SAAS) services for use in developing and prioritizing lead compounds for drug development; software as a service (SAAS) services in the field of biochemistry; software as a service (SAAS) services in the field of biophysics; software as a service (SAAS) services in the field of structural biology; software as a service (SAAS) services in the field of chemistry; software as a service (SAAS) services in the nature of a knowledge based drug discovery platform; software as a service (SAAS) services in the nature of data analysis software for use in drug discovery; software as a service (SAAS) services in the nature of drug discovery software utilizing hit finding techniques.